Bowers added that to increase access to the latest drugs, the "cancer system" must be organized in such a way as to ...

Today we highlight research findings reported at ESMO 2024, the annual meeting of the European Society of Medical Oncology.

Before the annual congress of the European Society for Medical Oncology began in Barcelona, clinicians held a press ...

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announces that the company will present updated data from the ...

About Renovaro Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted ...

ESMO24 - Pre-Meeting New Drug Classification OBiS Insights pre-meeting ESMO24 report is based on a review of the 2,960 abstract titles o ...

CEL-SCI to present new data for Multikine head & neck cancer immunotherapy at the European Society for Medical Oncology 2024 ...

Latest data of InnoCare’s (HKEX: 09969; SSE: 688428) orelabrutinib were presented at the European Society for Medical Oncology (ESMO) Congress 2024.

will be presented by Eisai at the European Society for Medical Oncology (ESMO) Congress 2024, held in Barcelona, Spain from September 13 to 17, 2024. The abstract of the study has been released today.

Pfizer Inc. (NYSE: PFE) continues to showcase potential practice-changing research and next-generation candidates across its robust Oncology portfolio at the European Society for Medical Oncology ...

Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) Congress ...